Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 36 min ago
Peer-reviewedCC BY-NC-ND 4.0Journal of the Pediatric Orthopaedic Society of North America

Surgical Outcomes of Pediatric Osteosarcoma Patients Treated With a Failed Allograft Reconstruction Revised to an Endoprosthesis

  • William Pavlis1
  • Roy Miloh2
  • Julien Montreuil3
  • Dominic Campano4
  • Erik J. Geiger1
  • Brooke Crawford1
  • Francis J. Hornicek1
  • H. Thomas Temple1
4 affiliations
  1. 1Department of Orthopaedics, University of Miami, Miami, FL, USA
  2. 2University of Miami Miller School of Medicine, Miami, FL, USA
  3. 3Department of Orthopaedic Surgery, McGill University Health Centre, Montreal, QC, Canada
  4. 4Department of Orthopedics and Sports Medicine, East Carolina University, Greenville, NC, USA
Read full textPDFDOICite

Abstract

Background: Allograft reconstructions offer unique benefits as a limb salvage option for pediatric osteosarcoma; however, failures are common and may require revision to an endoprosthesis. Currently, no study has analyzed outcomes following conversion from a failed allograft reconstruction to endoprosthesis in this population. The purpose of this study is to identify the outcomes of patients with pediatric osteosarcoma about the knee treated with an allograft later revised to an endoprosthesis and, secondarily, perform an exploratory comparison to similar patients treated primarily with an endoprosthesis.

Methods: We conducted a retrospective cohort study of pediatric patients with osteosarcoma of the distal femur or proximal tibia who underwent limb salvage between 1990 and 2024. The study cohort included patients initially treated with an allograft revised to an endoprosthesis. The comparison cohort included patients treated primarily with endoprostheses. Demographics, surgical outcomes, complications, Musculoskeletal Tumor Society (MSTS) scores, and functional range of motion (ROM) were collected and analyzed.

Results: Thirteen patients underwent revision from allograft to endoprosthesis and were compared to 48 patients treated primarily with endoprostheses. There were no significant differences in primary disease characteristics between the 2 cohorts. The outcomes from conversion to endoprosthesis were comparable to the primary endoprosthesis group with no significant differences in complication rates, MSTS scores, ROM, or revision rates between cohorts. Endoprosthesis survival at 5, 10, and 15 years in the allograft revision cohort was 92.3%, 76.9%, and 51.3%, respectively. On exploratory analysis, there was a significantly higher endoprosthesis implant survival in the allograft revision cohort (P = .02); however, this finding attenuated after exclusion of expandable implants from the primary endoprosthesis cohort (P = .21).

Conclusions: Revising pediatric osteosarcoma patients to endoprostheses following an initial biologic reconstruction presents a complex but viable option associated with a significant complication rate. Despite these challenges, most patients achieved satisfactory functional outcomes comparable to patients with primary endoprosthesis reconstructions in this exploratory analysis. These findings support allograft use as a viable initial option in select patients, offering the benefit of potential bone stock preservation and delayed endoprosthesis implantation without clear compromise of long-term outcomes.

Key Concepts: (1)This study foound satisfactory patient-reported, functional, and surgical outcomes in patients revised from an allograft to an endoprosthesis.

(2)We identified improved implant survival after revision to an endoprosthesis compared to prior studies.

(3)Allograft revision patients had comparable outcomes to patients with primary endoprosthetic reconstructions.

Level of Evidence: III

Related

  1. Enrichment-Free Rare Cell Profiling in Pediatric Osteosarcoma Reveals a Circulating Cell Population Associated with Relapse-Free Survival
    Stephanie N. Shishido, Siddhant Chaudhary, Ian Ward +7
    CancersPeer-reviewedCC BYFull textOncologyEurope PMC
  2. Anterior Spinal Reconstruction With Structural Femoral Allograft After En Bloc Spinal Tumor Resection in the Thoracolumbar Spine: A Case Series With Median 7-Year Follow-Up
    Jiong Hao Jonathan Tan, Simone Mazzoli, Ern Juan Jonathan Koh +4
    International Journal of Spine SurgeryPeer-reviewedLicence not statedFull textSurgery & anaesthesiaPMC
  3. Postoperative radiotherapy after tracheal reconstruction with cryopreserved aortic allograft for adenoid cystic carcinoma
    Arnaud Beddok, Nicolas Venissac, Marine Boulesteix +10
    Practical Radiation Oncology: An official journal of the American Society for Radiation OncologyPeer-reviewedLicence not statedFull textGeneral biologyGeneral medicineHAL
  4. Patellar Tendon Allograft Reconstruction Using Achilles Graft With Traversing Suprapatellar Cerclage Limbs
    Ronak J. Mahatme, Shawn A. Moore, Nishanth Muthusamy +3
    Arthroscopy techniquesPeer-reviewedCC BYFull textSurgery & anaesthesiaEurope PMCPMC
  5. The Boston All‐in‐One Medial Patellofemoral Complex Reconstruction: A Combined Medial Patellofemoral Ligament and Medial Quadriceps Tendon Femoral Ligament Dynamic Tensioning Technique Using Allograft
    Khalid Al-Hourani, Xinning Li
    Arthroscopy techniquesPeer-reviewedCC BYFull textSurgery & anaesthesiaEurope PMCEurope PMCPMC

Cite

BibTeXRIS
BibTeX
@article{pavlis2026surgical,
  title = {{Surgical Outcomes of Pediatric Osteosarcoma Patients Treated With a Failed Allograft Reconstruction Revised to an Endoprosthesis}},
  author = {William Pavlis and Roy Miloh and Julien Montreuil and Dominic Campano and Erik J. Geiger and Brooke Crawford and Francis J. Hornicek and H. Thomas Temple},
  journal = {Journal of the Pediatric Orthopaedic Society of North America},
  year = {2026},
  month = aug,
  doi = {10.1016/j.jposna.2026.100437},
  url = {https://doi.org/10.1016/j.jposna.2026.100437},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Surgical Outcomes of Pediatric Osteosarcoma Patients Treated With a Failed Allograft Reconstruction Revised to an Endoprosthesis
AU  - William Pavlis
AU  - Roy Miloh
AU  - Julien Montreuil
AU  - Dominic Campano
AU  - Erik J. Geiger
AU  - Brooke Crawford
AU  - Francis J. Hornicek
AU  - H. Thomas Temple
PY  - 2026
DA  - 2026/08/10
JO  - Journal of the Pediatric Orthopaedic Society of North America
DO  - 10.1016/j.jposna.2026.100437
UR  - https://doi.org/10.1016/j.jposna.2026.100437
AB  - Background: Allograft reconstructions offer unique benefits as a limb salvage option for pediatric osteosarcoma; however, failures are common and may require revision to an endoprosthesis. Currently, no study has analyzed outcomes following conversion from a failed allograft reconstruction to endoprosthesis in this population. The purpose of this study is to identify the outcomes of patients with pediatric osteosarcoma about the knee treated with an allograft later revised to an endoprosthesis and, secondarily, perform an exploratory comparison to similar patients treated primarily with an endoprosthesis.  Methods: We conducted a retrospective cohort study of pediatric patients with osteosarcoma of the distal femur or proximal tibia who underwent limb salvage between 1990 and 2024. The study cohort included patients initially treated with an allograft revised to an endoprosthesis. The comparison cohort included patients treated primarily with endoprostheses. Demographics, surgical outcomes, complications, Musculoskeletal Tumor Society (MSTS) scores, and functional range of motion (ROM) were collected and analyzed.  Results: Thirteen patients underwent revision from allograft to endoprosthesis and were compared to 48 patients treated primarily with endoprostheses. There were no significant differences in primary disease characteristics between the 2 cohorts. The outcomes from conversion to endoprosthesis were comparable to the primary endoprosthesis group with no significant differences in complication rates, MSTS scores, ROM, or revision rates between cohorts. Endoprosthesis survival at 5, 10, and 15 years in the allograft revision cohort was 92.3%, 76.9%, and 51.3%, respectively. On exploratory analysis, there was a significantly higher endoprosthesis implant survival in the allograft revision cohort (P = .02); however, this finding attenuated after exclusion of expandable implants from the primary endoprosthesis cohort (P = .21).  Conclusions: Revising pediatric osteosarcoma patients to endoprostheses following an initial biologic reconstruction presents a complex but viable option associated with a significant complication rate. Despite these challenges, most patients achieved satisfactory functional outcomes comparable to patients with primary endoprosthesis reconstructions in this exploratory analysis. These findings support allograft use as a viable initial option in select patients, offering the benefit of potential bone stock preservation and delayed endoprosthesis implantation without clear compromise of long-term outcomes.  Key Concepts: (1)This study foound satisfactory patient-reported, functional, and surgical outcomes in patients revised from an allograft to an endoprosthesis.  (2)We identified improved implant survival after revision to an endoprosthesis compared to prior studies.  (3)Allograft revision patients had comparable outcomes to patients with primary endoprosthetic reconstructions.  Level of Evidence: III
SN  - 2768-2765
ER  -